Segments

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segments

Segments

We manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the years ended December 31,
(In thousands)	2021		2020		2019
Revenue from services:
Pharmaceutical	$	—	$	—	$	—
Diagnostics	1,607,106		1,262,242		716,434
Corporate	—		—		—
	$	1,607,106	$	1,262,242	$	716,434
Revenue from products:
Pharmaceutical	$	141,770	$	119,952	$	112,184
Diagnostics	—		—		—
Corporate	—		—		—
	$	141,770	$	119,952	$	112,184
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	25,842	$	36,979	$	72,521
Diagnostics	—		16,240		—
Corporate	—		—		796
	$	25,842	$	53,219	$	73,317
Operating income (loss):
Pharmaceutical	$	(19,051)	$	(43,519)	$	(109,062)
Diagnostics	98,067		138,922		(123,359)
Corporate	(60,266)		(37,689)		(41,631)
	$	18,750	$	57,714	$	(274,052)
Depreciation and amortization:
Pharmaceutical	$	26,427	$	29,001	$	30,073
Diagnostics	52,289		56,361		63,675
Corporate	—		—		59
	$	78,716	$	85,362	$	93,807
Loss from investment in investees:
Pharmaceutical	$	(629)	$	(480)	$	(2,900)
Diagnostics	—		—		—
Corporate	—		—		—
	$	(629)	$	(480)	$	(2,900)
Revenues:
U.S.	$	1,640,354	$	1,317,766	$	751,099
Ireland	32,809		43,920		81,170
Chile	63,798		44,153		33,642
Spain	22,682		16,932		18,747
Israel	3,563		4,251		8,769
Mexico	11,005		7,865		8,032
Other	507		526		476
	$	1,774,718	$	1,435,413	$	901,935

(In thousands)	December 31, 2021		December 31, 2020
Assets:
Pharmaceutical	$	1,114,460	$	1,176,245
Diagnostics	1,238,583		1,268,738
Corporate	46,672		28,080
	$	2,399,715	$	2,473,063
Goodwill:
Pharmaceutical	$	237,576	$	245,793
Diagnostics	283,025		434,809
Corporate	—		—
	$	520,601	$	680,602

No customer represented more than 10% of our total consolidated revenue during the years ended December 31, 2021, 2020 and 2019. As of December 31, 2021 and 2020, no customer represented more than 10% of our accounts receivable balance.

The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 

(In thousands)	December 31, 2021		December 31, 2020
PP&E:
U.S.	$	50,559	$	73,564
Foreign	29,168		66,990
Total	$	79,727	$	140,554